11 Mar 2021

COVID-19, la ricerca accende i riflettori sull'argomento vaccini – Radio Fantastica

Su Radio Fantastica è intervenuto il Prof. Francesco Pappalardo docente di Informatica dell'Università degli Studi di Catania.

Ascolta l'intervista su YouTube: https://youtu.be/DIbDib6JmZA

Read more...
10 Mar 2021

UISS released as open-source

Today the COMBINE group releases as open-source (under Apache License v2.0) the main core of UISS in silico trial platform.

You can find the source code following this link: https://www.combine-group.org/assets/attachment/UISS_free.tgz

Read more...
8 Mar 2021

Antibodies therapeutics are partially ineffective on patients with severe COVID-19

Antibodies therapeutics are unable to protect patients with severe SARS-CoV-2 infection. This is the study conclusion by the COMBINE group of the University of Catania and published in the prestigious scientific journal BMC Bioinformatics

"The study had been carried out during the COVID-19 emergency in the spring of last year and…

Read more...
21 Nov 2020

SHARPER Night 2020 – CATANIA – Come nasce un farmaco

A seminar entitled "Come nasce un farmaco" will be held on November 26, 2020 from 4 to 4.30 pm.

Link to join on MS Teams: https://www.sharper-night.it/evento/conferenza-come-nasce-un-farmaco/
Code for join: i7qdx35

Official Site: https://www.sharper-night.it/

#sharpernight #sharpernightcatania #insilico #insilicotrials #insilicomedicine #combinegroup

Read more...
21 Nov 2020

SHARPER Night 2020 – CATANIA – Università Imprenditoriale

A seminar entitled "Università Imprenditoriale" will be held on November 23, 2020 from 10.30 to 11.45 am.

Event link: https://www.sharper-night.it/evento/conferenza-universita-imprenditoriale/

Official Site: https://www.sharper-night.it/

#sharpernight #sharpernightcatania #insilico #insilicotrials #insilicomedicine #combinegroup

Read more...
4 Nov 2020

In Silico World: Innovative solutions and new technologies to speed up the drug development

The overall aim of the In Silico World project is to accelerate the uptake of modelling and simulation technologies for the development and regulatory assessment of all kind of medical products.

This will be achieved by supporting the trajectory of a number of In Silico Trials solutions through development, validation, regulatory…

Read more...
15 Jun 2020

UISS, il paziente virtuale – Radio24 (IlSole24Ore)

Evitare, o ridurre al lumicino, la sperimentazione sugli animali; accelerare il processo di approvazione dei farmaci e scansare i vicoli ciechi nella ricerca.
Sono questi gli obiettivi cui punta un gruppo di ricercatori dell'Università di Catania con Uiss, il paziente virtuale. Uiss sta per Universal Immune System Simulator, è frutto…

Read more...
6 May 2020

COMBINE Group is dedicated to the testing and prediction of COVID-19 candidate vaccines efficacy using its in silico UISS platform.

To promptly and rapidly respond to pandemic events, the application of in silico trials can be used for designing and testing medicines against SARS-CoV-2 and speed-up the vaccine discovery pipeline, predicting any therapeutic failure and minimizing undesired effects. We just released (and submitted for possible consideration in one of the…

Read more...
30 Oct 2019

3TR Kick-off meeting

COMBINE Group (University of Catania) is one of the partner of 3TR project, the largest-ever Innovative Medicine Initiative 2 (IMI2) immunology project to improve disease management of non-responders to therapy across seven immune-mediated diseases.

Read on: Full Description of 3TR and See the video

Read more...
01 Oct 2019

Maintaining European scientific excellence and global leadership in TB Vaccine R&D

Maintaining European scientific excellence and global leadership in TB Vaccine R&D

Document Link

Read more...
04 Jul 2019

STriTuVaD simulation platform now able to reproduce the immune system response induced by vaccines

Another important milestone has been reached by the STriTuVaD project in these days.

The team of the University of Catania (Italy) successfully extended their modeling framework in order to include dynamics and specific features of…

Read more...
23 Jan 2019

STriTuVaD consortium meeting lays down the foundations for a fruitful EU-India cooperation in the fight against Tuberculosis

STriTuVaD consortium meeting lays down the foundations for a fruitful EU-India cooperation in the fight against Tuberculosis

Document Link

Read more...
17 Dec 2018

STriTuVaD consortium plan its regulatory strategy

STriTuVaD consortium plan its regulatory strategy.

 

Document Link

Read more...
14 Dec 2018

Can new drugs be tested with computers? EU-funded team explores the future of tuberculosis drugs testing

Can new drugs be tested with computers? EU-funded team explores the future of tuberculosis drugs testing.

, , , ,

 

Read more...

06 Jun 2018

COMBINE Group pioneers one of the first in silico trial approach

The most important financial newspaper in Italy recently published an article about the scientific coordination  of the COMBINE Group in the EC Horizon 2020 funded project STriTuVaD.

 

 

Read more...
17 Mar 2018

STriTuVaD Kick off meeting

Friday, 16 March 2018

On February 1, STriTuVaD project officially started.

The StriTuVaD multidisciplinary consortium, will deliver an in silico trial platform to simulate the relevant individual human physiology and physiopathology in patients affected by Mycobacterium tuberculosis. Virtual populations of individuals (a set of libraries of virtual patients for re-use in…

Read more...
13 May 2017

Call for papers: Cancer Immunotherapy and Vaccines

Guest Editor: Professor Francesco Pappalardo

 

BMC Immunology is currently accepting manuscripts to the new thematic series “Cancer Immunotherapy and Vaccines”.

The purpose of this thematic series is to bring together the latest advances in both biological and…

Read more...